EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study

Sumaiah J Alarfaj iD, Mostafa M Bahaa iD, Thanaa A Elmasry, Eman I Elberri, Eman El-Khateeb iD, Amir O Hamouda iD, Muhammed M Salahuddin, Marwa Kamal, Abdel-Naser Abdel-Atty Gadallah, Nashwa Eltantawy, Mohamed Yasser, Walaa A Negm iD und 5 weitere

Drug Design, Development and Therapy · 2024

DOI: 10.2147/dddt.s490772 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Sumaiah J Alarfaj und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Fenofibrate, Colitis, Ulcerative, NLR Family, Pyrin Domain-Containing 3 Protein, Sirtuin 1. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenofibrateColitis, UlcerativeNLR Family, Pyrin Domain-Containing 3 ProteinSirtuin 1AMP-Activated Protein KinasesHumansMaleFemaleAdultPilot ProjectsMiddle AgedInflammationMesalamineYoung AdultPPAR alpha

Stichwörter der Autor:innen

FenofibrateMesalamineNLRP3/AMPKPPARαUlcerative colitis

Substanzen

FenofibrateNLR Family, Pyrin Domain-Containing 3 ProteinSirtuin 1AMP-Activated Protein KinasesNLRP3 protein, humanSIRT1 protein, humanMesalaminePPAR alpha

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.

ORCID-Profile: Sumaiah J Alarfaj, Mostafa M Bahaa, Eman El-Khateeb, Amir O Hamouda, Walaa A Negm, Amsha S Alsegiani, Mamdouh Eldesoqui, Mahmoud S Abdallah

Zitieren

APA

Alarfaj, S. J., Bahaa, M. M., Elmasry, T. A., Elberri, E. I., El-Khateeb, E., Hamouda, A. O., Salahuddin, M. M., Kamal, M., Gadallah, A. A., Eltantawy, N., Yasser, M., Negm, W. A., Hamouda, M. A., Alsegiani, A. S., Alrubia, S., Eldesoqui, M., & Abdallah, M. S. (2024). Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s490772

Vancouver

Alarfaj SJ, Bahaa MM, Elmasry TA, Elberri EI, El-Khateeb E, Hamouda AO, et al. Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s490772

BibTeX
@article{Alarfaj2024,
  author = {Alarfaj, Sumaiah J and Bahaa, Mostafa M and Elmasry, Thanaa A and Elberri, Eman I and El-Khateeb, Eman and Hamouda, Amir O and Salahuddin, Muhammed M and Kamal, Marwa and Gadallah, Abdel-Naser Abdel-Atty and Eltantawy, Nashwa and Yasser, Mohamed and Negm, Walaa A and Hamouda, Manal A and Alsegiani, Amsha S and Alrubia, Sarah and Eldesoqui, Mamdouh and Abdallah, Mahmoud S},
  title = {Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  doi = {10.2147/dddt.s490772}
}
Kostenlos starten →